Table of Contents
Executive Summary — 5
SWOT
Analysis — 7
Nigeria Pharmaceuticals And Healthcare
Industry SWOT — 7
Nigeria Political
SWOT — 8
Nigeria Economic SWOT — 9
Nigeria Business Environment SWOT — 9
Pharmaceutical
Business Environment Ratings — 10
Table: Middle East And
Africa (MEA) – Regional Pharmaceutical Business Environment Ratings for
Q309 — 10
Limits To Potential
Returns — 11
Risks To Realisation Of
Returns — 12
Nigeria – Market
Summary — 13
Regulatory Regime — 14
Recent Regulatory Developments — 15
Intellectual Property
Regime — 18
Counterfeit Drugs — 18
Recent Developments in Regards to Counterfeit Drugs — 20
Pricing And Reimbursement Regime — 22
Industry
Developments — 23
Epidemiology — 23
Maternal and Child Health — 24
Communicable
Diseases — 25
HIV/AIDS — 26
Recent
Infectious Diseases Developments — 28
Healthcare
Sector — 28
Healthcare Financing — 29
Healthcare Provision — 30
Recent Healthcare Sector
Developments — 31
Healthcare
Reforms — 32
Health Insurance — 33
Traditional African Medicine — 35
Domestic Pharmaceutical
Sector — 36
Recent Domestic Company
Developments — 38
Foreign Pharmaceutical
Sector — 41
National Drug Policy — 42
Research and Development — 44
Medical
Devices — 45
Recent Developments In The Medical Devices
Market — 46
Table: Nigeria Free Zones: Key
Incentives — 46
Industry Forecast
Scenario — 48
Overall Market
Forecasts — 48
Table: Nigeria – Drug Market
Expenditure Indicators, Historical Data and Forecasts — 49
Key Growth Factors – Industry — 50
Table: Nigeria
– Health Expenditure Indicators, Historical Data and
Forecasts — 51
Key Growth Factors –
Macroeconomic — 52
Table: Nigeria - Economic Activity,
2006-2013 — 55
Prescription Drug Market
Forecast — 56
Table: Nigeria’s Prescription Drug
Market Indicators, Historical Data and Forecasts (US$mn unless otherwise
stated) — 57
Patented Drug Market
Forecast — 58
Table: Nigeria – Patented Drug Market
Indicators, Historical Data and Forecasts, 2003-2013 — 58
Generic Drug Market Forecast — 59
Table: Nigeria –
Generic Drug Market Indicators, Historical Data and Forecasts,
2003-2013 — 59
OTC Drug Market
Forecast — 60
Table: Nigeria – OTC Market Data
Indicators, Historical Data and Forecasts (NGNmn unless otherwise
stated) — 62
Pharmaceutical Import/Export
Forecasts — 63
Table: Nigeria – Pharmaceutical Trade
Indicators, Historical Data and Forecasts (US$mn),
2003-2013 — 64
Other Healthcare Data
Forecasts — 65
Table: Nigeria – Other Health
Indicators, Historical Data and Forecasts — 65
Key Risks
To BMI’s Forecasts — 66
Competitive
Landscape — 67
Company Monitor — 68
Multinational Company Profiles — 68
Pfizer — 68
Novartis — 71
Sanofi-Aventis — 72
GlaxoSmithKline
(GSK) — 73
Merck & Co — 74
Indigenous
Producers — 75
Nigeria-German Chemicals PLC
(NGC) — 75
Emzor — 77
Fidson
Healthcare — 79
Archy — 81
Neros
Pharmaceuticals — 82
Drugfield Pharmaceuticals
Limited — 83
Neimeth — 84
Country
Snapshot: Nigeria Demographic Data — 85
Section 1:
Population — 85
Table: Demographic Indicators,
2005-2030 — 85
Table: Rural/Urban Breakdown,
2005-2030 — 86
Section 2: Education And
Healthcare — 86
Table: Education,
2002-2005 — 86
Table: Vital Statistics,
2005-2030 — 86
Section 3: Labour Market And Spending
Power — 87
Table: Consumer Expenditure, 2000-2012
(US$) — 87
BMI Forecast Modelling — 88
How We Generate Our Pharmaceutical Industry Forecasts — 88
Pharmaceutical Business Environment Ratings
Methodology — 88
Ratings Overview — 89
Table: Pharmaceutical Business Environment Indicators — 90
Weighting — 91
Table: Weighting Of
Components — 91
Sources — 91
| 
View Cart
